BYETTA is the first FDA-approved GLP-1 receptor agonist for the treatment of type 2 diabetes.
百泌达是FDA批准的治疗2型糖尿病的首个GLP- 1受体激动剂药物。
AIM: to investigate the role of protease-activated receptor-2 (PAR-2) agonist in the formation and pathogenesis of stress ulcer.
目的：探讨大鼠蛋白酶激活受体- 2在应激性溃疡中的作用。
AIM: to investigate the role of protease-activated receptor-2 (PAR-2) agonist in the formation and pathogenesis of stress ulcer.
目的：探讨大鼠蛋白酶激活受体- 2在应激性溃疡中的作用。
应用推荐